Alluvi, known as BI 4744, presents a notable development in obesity treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide targets demonstrates remarkable efficacy in patient https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/